10月21日,比利时制药公司Galapagos宣布:因出售细胞治疗业务的尝试未果,将逐步关停该业务板块,寻求转型。此次业务调整将将导致全球约365名员工失业,波及美国、欧洲和中国地区。Galapagos还将关闭位于荷兰、瑞士、美国及中国的多个研发基地。该举措预计将产生约1.74亿至2.32亿美元的一次性支出,并在2025年第四季度至2026年间产生约1.16亿至1.45亿美元的运营成本。随即,...
Source Link10月21日,比利时制药公司Galapagos宣布:因出售细胞治疗业务的尝试未果,将逐步关停该业务板块,寻求转型。此次业务调整将将导致全球约365名员工失业,波及美国、欧洲和中国地区。Galapagos还将关闭位于荷兰、瑞士、美国及中国的多个研发基地。该举措预计将产生约1.74亿至2.32亿美元的一次性支出,并在2025年第四季度至2026年间产生约1.16亿至1.45亿美元的运营成本。随即,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.